These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37252367)

  • 1. An HR2-Mimicking Sulfonyl-γ-AApeptide Is a Potent Pan-coronavirus Fusion Inhibitor with Strong Blood-Brain Barrier Permeability, Long Half-Life, and Promising Oral Bioavailability.
    Xue S; Xu W; Wang L; Wang X; Duan Q; Calcul L; Wang S; Liu W; Sun X; Lu L; Jiang S; Cai J
    ACS Cent Sci; 2023 May; 9(5):1046-1058. PubMed ID: 37252367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein.
    Xue S; Wang X; Wang L; Xu W; Xia S; Sun L; Wang S; Shen N; Yang Z; Huang B; Li S; Cao C; Calcul L; Sun X; Lu L; Cai J; Jiang S
    Cell Discov; 2022 Sep; 8(1):88. PubMed ID: 36075899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases.
    Zhou J; Xu W; Liu Z; Wang C; Xia S; Lan Q; Cai Y; Su S; Pu J; Xing L; Xie Y; Lu L; Jiang S; Wang Q
    Acta Pharm Sin B; 2022 Apr; 12(4):1652-1661. PubMed ID: 34367893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helical sulfonyl-γ-AApeptides for the inhibition of HIV-1 fusion and HIF-1α signaling.
    Zhao X; Liu H; Zhang JC; Cai J
    RSC Med Chem; 2024 May; 15(5):1418-1423. PubMed ID: 38784464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines.
    Guo L; Lin S; Chen Z; Cao Y; He B; Lu G
    Signal Transduct Target Ther; 2023 May; 8(1):197. PubMed ID: 37164987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring Highly Conserved Regions of SARS-CoV-2 Spike S2 Subunit as Targets for Fusion Inhibition Using Chimeric Proteins.
    Polo-Megías D; Cano-Muñoz M; Berruezo AG; Laumond G; Moog C; Conejero-Lara F
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.
    Li CJ; Chao TL; Chang TY; Hsiao CC; Lu DC; Chiang YW; Lai GC; Tsai YM; Fang JT; Ieong S; Wang JT; Chang SY; Chang SC
    Microbiol Spectr; 2022 Apr; 10(2):e0181421. PubMed ID: 35293796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor
    Lu Y; Shen F; He W; Li A; Li M; Feng X; Zheng Y; Pang W
    Acta Pharm Sin B; 2023 May; 13(8):3339-51. PubMed ID: 37360013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides.
    Hu Y; Zhu Y; Yu Y; Liu N; Ju X; Ding Q; He Y
    Antiviral Res; 2023 Apr; 212():105571. PubMed ID: 36868315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays.
    Curreli F; Ahmed S; Victor SMB; Drelich A; Panda SS; Altieri A; Kurkin AV; Tseng CK; Hillyer CD; Debnath AK
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants.
    Bi W; Chen G; Dang B
    J Virol; 2022 Jul; 96(13):e0068122. PubMed ID: 35735997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 Subunit.
    Kandeel M; Yamamoto M; Tani H; Kobayashi A; Gohda J; Kawaguchi Y; Park BK; Kwon HJ; Inoue JI; Alkattan A
    Biomol Ther (Seoul); 2021 May; 29(3):282-289. PubMed ID: 33424013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational Design of Sulfonyl-γ-AApeptides as Highly Potent HIV-1 Fusion Inhibitors with Broad-Spectrum Activity.
    Xue S; Xu W; Wang L; Xu L; Calcul L; Teng P; Lu L; Jiang S; Cai J
    J Med Chem; 2023 Sep; 66(18):13319-13331. PubMed ID: 37706450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.
    Bosch BJ; Martina BE; Van Der Zee R; Lepault J; Haijema BJ; Versluis C; Heck AJ; De Groot R; Osterhaus AD; Rottier PJ
    Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8455-60. PubMed ID: 15150417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern.
    Xing L; Xu X; Xu W; Liu Z; Shen X; Zhou J; Xu L; Pu J; Yang C; Huang Y; Lu L; Jiang S; Liu S
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35337003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Repurposing of Itraconazole and Estradiol Benzoate against COVID-19 by Blocking SARS-CoV-2 Spike Protein-Mediated Membrane Fusion.
    Yang C; Pan X; Huang Y; Cheng C; Xu X; Wu Y; Xu Y; Shang W; Niu X; Wan Y; Li Z; Zhang R; Liu S; Xiao G; Xu W
    Adv Ther (Weinh); 2021 May; 4(5):2000224. PubMed ID: 33786369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life.
    Duan Q; Xia S; Jiao F; Wang Q; Wang R; Lu L; Jiang S; Xu W
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern.
    Schmitz KS; Geers D; de Vries RD; Bovier TF; Mykytyn AZ; Geurts van Kessel CH; Haagmans BL; Porotto M; de Swart RL; Moscona A
    mBio; 2022 Jun; 13(3):e0124922. PubMed ID: 35695453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants.
    Ko SH; Chen WY; Su SC; Lin HT; Ke FY; Liang KH; Hsu FF; Kumari M; Fu CY; Wu HC
    J Biomed Sci; 2022 Dec; 29(1):108. PubMed ID: 36550570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.